OrbiMed Buys $16.15M in ADARx IPO, Converts 23.3M Preferred Shares
ADRX is trading near its 52-week low of $18.5 (9.7% above the low).
Summary
OrbiMed Advisors bought $16.15M of ADARx common stock at the $17.00 IPO price and converted 23.3M preferred shares into common stock upon the IPO closing.
Key Events · Ownership and Investor Activity · ADRX
-
OrbiMed Buys $16.15M at IPO Price
OrbiMed Advisors purchased 950,000 shares at $17.00 per share for $16.15 million in ADARx's IPO, which closed September 28, 2026.
-
Preferred Conversion Adds 23.3M Shares
OrbiMed converted 23,255,789 shares of Series A, B, B-1, and C preferred stock into common stock on a 1-for-1.1717 basis upon IPO closing.
-
Post-Transaction Holdings
OrbiMed entities hold 14,325,529 shares indirectly across multiple funds, with Carl L. Gordon and Erez Chimovits serving on ADARx's board.
-
IPO Context
Follows ADARx's $446.3 million upsized IPO and $89.3 million AbbVie private placement, both closed September 28, 2026.
Analysis · ADRX · Life Sciences
A major healthcare investment firm and 10% owner, OrbiMed Advisors, purchased 950,000 shares at the $17.00 IPO price for $16.15 million and converted 23.3 million preferred shares into common stock upon ADARx's IPO closing. This follows the $446 million upsized IPO and $89.3 million AbbVie private placement that closed September 28. OrbiMed's open-market purchase at the IPO price demonstrates conviction from a sophisticated life-sciences investor, while the preferred conversion adds significant common stock to the float.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADRX was trading at $20.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.50 to $23.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.